Hemcheck Sweden AB has received a preliminary approval, a so-called Notice of Allowance, from the USPTO regarding Hemcheck’s design right application for its reader. When this application is finally approved, Hemcheck will have IP-protection for the design of its reader in the US as well as in Europe, where the design application has been approved since earlier.

–It’s good news that we have gotten this preliminary approval, since it strengthens our portfolio of IP-protection of our products, says Hemcheck CEO Joen Averstad.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com 

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.